Mersana Therapeutics Signs $334 Million R&D Deal

Mersana Therapeutics Inc. has signed an exclusive research and licensing agreement with Teva Pharmaceutical Industries Ltd., to develop and commercialize a novel fumagillin analog for the treatment of all indications, including cancer. The deal could be worth upwards of $334 million. Cambridge, Mass.-based Mersana Therapeutics has raised around $36 million in VC funding from Fidelity Biosciences, Harris & Harris Group, PureTech Ventures, ProQuest Investments and Rho Ventures.